Biomarkers for Pharmacoresponse in Bipolar Disorder - Coagulation
NCT ID: NCT06581822
Last Updated: 2025-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
68 participants
OBSERVATIONAL
2017-02-24
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lithium Versus Lamotrigine in Bipolar Disorder, Type II
NCT06184581
Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder
NCT00563992
Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium
NCT01919892
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
NCT00596622
Medical Comorbidities in Bipolar Disorder
NCT06872398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* using a case-control design where cases are bipolar patients not yet treated with lithium, and controls are healthy volunteers (Swedish ethical review authority Dnr 2023-05799-02, PI Kristoffer Månsson, KI).
* using a prospective cohort design, following the patients over time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Catharina Lavebratt Holmquist
Research group leader
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska Institutet
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-04886-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.